Displaying drugs 10501 - 10525 of 12439 in total
Bertilimumab
Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.
Investigational
Matched Description: … It is developed by MedImmune for the treatment of Allergic Rhinitis. ... Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic …
Ulixertinib
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.
Investigational
Matched Description: … It is currently in clinical trials for the treatment of a wide range of tumors. …
Serabelisib
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Investigational
Matched Description: … investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of ... Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) …
ABT-072
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
Investigational
Matched Description: … Multiple Doses of ABT-072 Used to Treat Hepatitis C). ... Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of …
2X-121
2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).
Investigational
Matched Description: … 2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and ... Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X …
Bleselumab
Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients).
Investigational
Matched Description: … Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of ... Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant …
Lifastuzumab vedotin
Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
Investigational
Matched Description: … Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of ... Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant …
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. ... It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. …
Peginterferon alfacon-1
PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small molecules, and other drugs. [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients...
Investigational
Matched Description: … PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to ... [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients ... a broad range of drug substances such as peptides and proteins including antibody fragments; small molecules …
OAV201
OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter. It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical...
Investigational
Matched Description: … a segment of the murine MECP2 promoter. ... serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of ... It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation …
MIV-701
MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Investigational
Matched Description: … It is developed for the treatment of osteoporosis. ... MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. …
Filociclovir
Filociclovir is under investigation in clinical trial NCT01433835 (Safety and Pharmacokinetics of Single Oral Doses of Filociclovir in Healthy Volunteers).
Investigational
Matched Description: … Oral Doses of Filociclovir in Healthy Volunteers). ... Filociclovir is under investigation in clinical trial NCT01433835 (Safety and Pharmacokinetics of Single …
Nevanimibe
Nevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome).
Investigational
Matched Description: … of Endogenous Cushing's Syndrome). ... Nevanimibe is under investigation in clinical trial NCT03053271 (A Study of ATR-101 for the Treatment …
DSP107
DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPĪ± and 4-1BBL.
Investigational
Matched Description: … of SIRPĪ± and 4-1BBL. ... DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain …
OSI-7836
OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. It is also more active than ara-C (another clinically used nucleoside...
Investigational
Matched Description: … OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader ... The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. …
Horse chestnut
Horse chestnut is a flowering plant commonly referred to as Aesculus hippocastanum. Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of bleeding due to anticoagulant actions. These seeds are processed to remove the toxic component, resulting in purified horse chestnut seed extract...
Experimental
Matched Description: … the veins and reduces swelling and inflammation of the legs. ... Its therapeutic potential in the treatment of chronic venous insufficiency is being studied. ... horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of …
Pemivibart
Pemivibart (Pemgarda) is a half life-extended monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. It received emergency use authorization (EUA) by the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.
Investigational
Matched Description: … received emergency use authorization (EUA) by the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of …
Technetium Tc-99m arcitumomab
Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons.
Experimental
Matched Description: … The molecule has a molecular weight of ~54,000 Daltons. ... Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity …
Beta-D-Glucose
A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.
Experimental
Matched Description: … A primary source of energy for living organisms. ... It is naturally occurring and is found in fruits and other parts of plants in its free state. …
INS 316
INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.
Investigational
Matched Description: … of lung diseases, including lung cancer. ... INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis …
IMCY-0141
IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves.
Investigational
Matched Description: … multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves. ... MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of …
R1295
R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.
Investigational
Matched Description: … R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis ... Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid …
OC-1012
OC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.
Investigational
Matched Description: … mucositis, a serious side effect of chemotherapy and head and neck radiation therapy. ... 1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of …
Debamestrocel
Debamestrocel consists of autologous mesenchymal stromal cells secreting neurotrophic factors. Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Investigational
Matched Description: … Debamestrocel consists of autologous mesenchymal stromal cells secreting neurotrophic factors. ... under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of …
NCX 1022
NCX is an NO-releasing derivative of hydrocortisone.
Investigational
Matched Description: … NCX is an NO-releasing derivative of hydrocortisone. …
Displaying drugs 10501 - 10525 of 12439 in total